Hongkai Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongkai Wang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Baojun Liu
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China
1 shared publication - Cheng Huang
Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
1 shared publication Dingwei Ye
Department of Urology Fudan University Shanghai Cancer Center Shanghai China
1 shared publication- Junlong Wu
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
1 shared publication Shanshan Wang
Department of Urology Fudan University Shanghai Cancer Center Shanghai China
1 shared publication- Ting Zhang
Department of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai, 200040, China, huashan.org.cn
1 shared publication
Latest Publications
- 5 October 2026
- Published by Wiley in BJU International
Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone‐sensitive prostate cancer: the ARASENS and LATITUDE trials
Objectives: To assess whether treatment‐period serum testosterone breakthrough >35 ng/dL is associated with clinical outcomes during intensified therapy for metastatic hormone‐sensitive prostate cancer. Patients and Methods: We performed post hoc analyses of the experimental arms of the ARASENS (darolutamide plus androgen deprivation therapy [ADT] and docetaxel; ClinicalTrials.gov identifier NCT02799602) and LATITUDE (abiraterone acetate plus prednisone and ADT; NCT01715285) phase III trials. Cohort‐specific fixed‐window landmark analyses classified exposure as any eligible testosterone result >35 ng/dL after treatment initiation and through Day 147 in the LATITUDE trial or Day 266 in the ARASENS trial. Treatment‐initiation/Day‐1 and end‐of‐treatment measurements were excluded. Follow‐up began at the landmark. The primary outcome was overall survival (OS); the LATITUDE progression‐free survival (PFS) and the ARASENS time to castration‐resistant prostate cancer (CRPC) were progression endpoints. Multivariable Cox regression was primary; landmark and time‐dependent sensitivity analyses were also performed. Results: At the landmark, 564 LATITUDE and 578 ARASENS patients were classifiable for OS. In the LATITUDE trial, breakthrough was associated with worse OS (adjusted hazard ratio [HR], 1.49, 95% confidence interval [CI] 1.07–2.08; P = 0.019); the PFS estimate was directionally similar but imprecise (HR 1.40, 95% CI 0.98–2.00; P = 0.065). In the ARASENS trial, the overall associations were not statistically significant for OS (HR 1.18, 95% CI 0.85–1.62; P = 0.322) or CRPC (HR 0.86, 95% CI, 0.60–1.23; P = 0.397). Exploratory piecewise modelling suggested time variation for CRPC (interaction P = 0.028). Conclusion: Testosterone breakthrough >35 ng/dL was associated with worse post‐landmark OS in the LATITUDE trial, whereas the overall associations with OS and CRPC in the ARASENS trial were not statistically significant. These within‐cohort findings are exploratory and do not establish causality, a difference between treatment mechanisms, or a clinical testosterone target.
- 5 October 2026
- Published by Wiley in BJU International
Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone‐sensitive prostate cancer: the ARASENS and LATITUDE trials
Objectives: To assess whether treatment‐period serum testosterone breakthrough >35 ng/dL is associated with clinical outcomes during intensified therapy for metastatic hormone‐sensitive prostate cancer. Patients and Methods: We performed post hoc analyses of the experimental arms of the ARASENS (darolutamide plus androgen deprivation therapy [ADT] and docetaxel; ClinicalTrials.gov identifier NCT02799602) and LATITUDE (abiraterone acetate plus prednisone and ADT; NCT01715285) phase III trials. Cohort‐specific fixed‐window landmark analyses classified exposure as any eligible testosterone result >35 ng/dL after treatment initiation and through Day 147 in the LATITUDE trial or Day 266 in the ARASENS trial. Treatment‐initiation/Day‐1 and end‐of‐treatment measurements were excluded. Follow‐up began at the landmark. The primary outcome was overall survival (OS); the LATITUDE progression‐free survival (PFS) and the ARASENS time to castration‐resistant prostate cancer (CRPC) were progression endpoints. Multivariable Cox regression was primary; landmark and time‐dependent sensitivity analyses were also performed. Results: At the landmark, 564 LATITUDE and 578 ARASENS patients were classifiable for OS. In the LATITUDE trial, breakthrough was associated with worse OS (adjusted hazard ratio [HR], 1.49, 95% confidence interval [CI] 1.07–2.08; P = 0.019); the PFS estimate was directionally similar but imprecise (HR 1.40, 95% CI 0.98–2.00; P = 0.065). In the ARASENS trial, the overall associations were not statistically significant for OS (HR 1.18, 95% CI 0.85–1.62; P = 0.322) or CRPC (HR 0.86, 95% CI, 0.60–1.23; P = 0.397). Exploratory piecewise modelling suggested time variation for CRPC (interaction P = 0.028). Conclusion: Testosterone breakthrough >35 ng/dL was associated with worse post‐landmark OS in the LATITUDE trial, whereas the overall associations with OS and CRPC in the ARASENS trial were not statistically significant. These within‐cohort findings are exploratory and do not establish causality, a difference between treatment mechanisms, or a clinical testosterone target.
- Open Access
- 14 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Icariin Alleviates Bleomycin‐Induced Idiopathic Pulmonary Fibrosis in Mice by Modulating the Gut–Lung Axis and Serum Metabolism
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of uncertain etiology with few specific and effective therapeutic agents approved for its treatment. We examined the underlying processes and the impact of icariin (ICA) on a bleomycin‐induced pulmonary fibrosis model. After giving ICA orally to the experimental mouse model for 4 weeks, the impact of the drug on pulmonary fibrosis was assessed by immunohistochemical analysis, Masson’s trichrome staining, and hematoxylin and eosin staining. 16S rRNA sequencing and 5R 16S rRNA sequencing were applied to investigate the compositions of the gut and lung microbiota, respectively. The alterations of serum metabolites were assessed using untargeted metabolomic technique. ICA treatment attenuated pulmonary fibrosis in the BLM‐induced mouse model. Meanwhile, ICA regulated the abundance and composition of pulmonary along with intestinal microbiota, especially Akkermansia and Lactobacillus . The strong connections between the intestinal and pulmonary microbiota supported the gut–lung axis. In addition, serum metabolic profiles and related metabolic pathways were influenced by ICA intervention. Spearman’s correlation analysis revealed that Akkermansia or Lactobacillus was significantly associated with various metabolites via corresponding metabolic pathways. ICA has a pulmonary‐protective effect against BLM‐induced pulmonary fibrosis, which appears to modulate serum metabolic profiles by affecting the Akkermansia- or Lactobacillus- involved gut–lung axis.
- 14 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessIcariin Alleviates Bleomycin‐Induced Idiopathic Pulmonary Fibrosis in Mice by Modulating the Gut–Lung Axis and Serum Metabolism
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of uncertain etiology with few specific and effective therapeutic agents approved for its treatment. We examined the underlying processes and the impact of icariin (ICA) on a bleomycin‐induced pulmonary fibrosis model. After giving ICA orally to the experimental mouse model for 4 weeks, the impact of the drug on pulmonary fibrosis was assessed by immunohistochemical analysis, Masson’s trichrome staining, and hematoxylin and eosin staining. 16S rRNA sequencing and 5R 16S rRNA sequencing were applied to investigate the compositions of the gut and lung microbiota, respectively. The alterations of serum metabolites were assessed using untargeted metabolomic technique. ICA treatment attenuated pulmonary fibrosis in the BLM‐induced mouse model. Meanwhile, ICA regulated the abundance and composition of pulmonary along with intestinal microbiota, especially Akkermansia and Lactobacillus . The strong connections between the intestinal and pulmonary microbiota supported the gut–lung axis. In addition, serum metabolic profiles and related metabolic pathways were influenced by ICA intervention. Spearman’s correlation analysis revealed that Akkermansia or Lactobacillus was significantly associated with various metabolites via corresponding metabolic pathways. ICA has a pulmonary‐protective effect against BLM‐induced pulmonary fibrosis, which appears to modulate serum metabolic profiles by affecting the Akkermansia- or Lactobacillus- involved gut–lung axis.